Dale L Bixby
Professor of Internal Medicine
[email protected]

Available to mentor
Dale L Bixby
Clinical Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      Real-world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan.
      Foucar CE, Foley DH, Aldous J, Burke PW, Pettit KR, Benitez LL, Perissinotti AJ, Marini BL, Boonstra P, Bixby DL. Eur J Haematol, 2024 Mar; 112 (3): 424 - 432. DOI:10.1111/ejh.14131
      PMID: 37929654
    • Journal Article
      Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
      Khouderchah CJ, Benitez LL, Marini BL, Fraga M, Pettit K, Burke PW, Bixby DL, Perissinotti AJ. Leuk Lymphoma, 2024 Feb; 65 (2): 228 - 234. DOI:10.1080/10428194.2023.2276056
      PMID: 37933203
    • Journal Article
      Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
      Altman JK, Zuckerman T, Koprivnikar J, McCloskey J, Kota V, Keng M, Frankfurt O, Abaza Y, Bixby DL, Emadi A, Burch M, Bhatnagar B, Luger SM, Percival M-E, Wolach O, Craig M, Ganzel C, Roboz G, Levi I, Gourevitch A, Flaishon L, Tessler S, Blumberg C, Gengrinovitch S, Ben Yakar R, Rowe JM. Blood Adv, 2023 Dec 26; 7 (24): 7494 - 7500. DOI:10.1182/bloodadvances.2023010943
      PMID: 37903324
    • Journal Article
      Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia.
      Shinn LT, Benitez LL, Perissinotti AJ, Reid JH, Buhlinger KM, van Deventer H, Barth D, Wagner CB, Zacholski K, Desai R, Soule A, Stump SE, Weis TM, Bixby D, Burke P, Pettit K, Marini BL. Int J Hematol, 2023 Dec; 118 (6): 682 - 689. DOI:10.1007/s12185-023-03670-3
      PMID: 37882977
    • Journal Article
      Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)
      Daver N, Stein AS, Bixby D, Chai-Ho W, Zeidner JF, Maher K, Stevens DA, Stahl M, Yee K, Curran EK, Ito S, Sochacki A, Sallman DA, Hernandez R, Metenou S, Ma B, Kato K, Zeidan AM. Blood, 2023 Nov 28; 142 (Supplement 1): 4278 DOI:10.1182/blood-2023-173991
    • Journal Article
      Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring.
      Coe-Eisenberg TD, Perissinotti AJ, Marini BL, Pettit KM, Bixby DL, Burke PW, Benitez L. Ann Hematol, 2023 Nov; 102 (11): 3133 - 3141. DOI:10.1007/s00277-023-05373-5
      PMID: 37480389
    • Journal Article
      P492: SAFETY AND EFFICACY OF LP‐108 AS MONOTHERAPY AND COMBINED WITH AZACITIDINE IN PATIENTS WITH RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR ACUTE MYELOID LEUKEMIA
      Koenig K, Burgues JMB, Montesinos P, Walker A, Bixby D, Burke P, Daver N, Konopleva M, Anthony S, Tan F, Chen Y, Chen Y, Shen Y, Curran E. HemaSphere, 7 (Suppl): e2546261 DOI:10.1097/01.hs9.0000968876.25462.61
    • Journal Article
      T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
      Gutierrez M, Bladek P, Goksu B, Murga-Zamalloa C, Bixby D, Wilcox R. Int J Mol Sci, 2023 Jul 28; 24 (15): DOI:10.3390/ijms241512106
      PMID: 37569479